<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Causes of hypopituitarism</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Causes of hypopituitarism</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Causes of hypopituitarism</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Snyder, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 30, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hypopituitarism refers to decreased secretion of pituitary hormones, which can result from diseases of the pituitary gland or from diseases of the hypothalamus. The latter cause diminished secretion of hypothalamic-releasing hormones, thereby reducing secretion of the corresponding pituitary hormones (<a class="graphic graphic_table graphicRef55951" href="/d/graphic/55951.html" rel="external">table 1</a>).</p><p>The clinical manifestations of hypopituitarism depend upon the cause as well as the type and degree of hormonal insufficiency. Patients may be asymptomatic or present with symptoms related to hormone deficiency or a mass lesion, or nonspecific symptoms such as fatigue.</p><p>The causes of hypopituitarism will be reviewed here. The clinical manifestations and treatment of hypopituitarism are discussed separately. (See  <a class="medical medical_review" href="/d/html/6637.html" rel="external">"Clinical manifestations of hypopituitarism"</a> and  <a class="medical medical_review" href="/d/html/6640.html" rel="external">"Treatment of hypopituitarism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>In a study that comprised two cross-sectional surveys (from 1992 and 1999) of over 146,000 adults in northern Spain, the prevalence of hypopituitarism was 29 of 100,000 in the first survey and 45.5 of 100,000 in the second [<a href="#rid1">1</a>]. A longitudinal survey was also performed; the average annual incidence of hypopituitarism was 4.2 cases of 100,000 (similar for males and females). In the second survey (which included most cases registered in the first survey), the causes of hypopituitarism included pituitary tumor (61 percent), nonpituitary tumor (9 percent), and a nontumor cause (30 percent).</p><p>A study of 773 adults with hypopituitarism found the following distribution of etiologies [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Nontumoral causes (approximately 50 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pituitary tumors (43.6 percent) (hypopituitarism due to direct effects of the tumor and/or treatment)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extrapituitary tumors (7.2 percent)</p><p></p><p class="headingAnchor" id="H523299073"><span class="h1">HYPOTHALAMIC DISORDERS</span><span class="headingEndMark"> — </span>Any disease involving the hypothalamus can affect secretion of one or more of the hypothalamic hormones that influence secretion of corresponding pituitary hormones. Unlike diseases that involve the pituitary directly, any of these conditions can also diminish the secretion of vasopressin, resulting in arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus). Pituitary lesions alone do not cause AVP-D, since some vasopressin-producing neurons terminate in the median eminence. (See  <a class="medical medical_review" href="/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p class="headingAnchor" id="H523299106"><span class="h2">Tumors</span><span class="headingEndMark"> — </span>These include benign tumors that arise in the hypothalamus, such as craniopharyngiomas, and malignant tumors that metastasize there, such as lung and breast carcinomas. (See <a class="local">'Epidemiology'</a> above and  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses"</a>.)</p><p class="headingAnchor" id="H523299124"><span class="h2">Radiation therapy</span><span class="headingEndMark"> — </span>Hypothalamic hormone deficiency often ensues when brain tumors or nasopharyngeal carcinomas are treated by radiation in children or adults [<a href="#rid3">3-8</a>]. Radiation-induced damage is usually due to injury at the level of the hypothalamus, which results in secondary deficiencies or dysregulation of the anterior pituitary hormones growth hormone (GH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and corticotropin (ACTH).</p><p>Children treated with radiation doses ≥18 Gy to the hypothalamic-pituitary axis are at risk for GH deficiency. Those treated with doses &gt;30 to 40 Gy are at risk for deficiencies of LH, FSH, TSH, and ACTH.</p><p>The risk of pituitary dysfunction after cranial radiation is both dose- and time-dependent and may not become apparent until many years after treatment. It is likely that systematic, risk-based screening will uncover large numbers of previously undiagnosed hormonal deficiencies in at-risk adult survivors of childhood cancer [<a href="#rid9">9,10</a>]. It is thus imperative for at-risk survivors of childhood cancer to have lifelong risk-based screening for hormonal abnormalities. (See  <a class="medical medical_review" href="/d/html/93313.html" rel="external">"Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood"</a>.)</p><p>In a retrospective study of 748 adult survivors of childhood cancer who were treated with cranial radiation and followed for a mean of 27 years, the prevalence of anterior pituitary hormone deficiencies was 46.5, 10.8, 7.5, and 4 percent for GH, LH/FSH, TSH, and ACTH respectively [<a href="#rid11">11</a>]. (See  <a class="medical medical_review" href="/d/html/93313.html" rel="external">"Endocrinopathies in cancer survivors and others exposed to cytotoxic therapies during childhood"</a>.)</p><p class="headingAnchor" id="H523299272"><span class="h2">Infiltrative lesions</span><span class="headingEndMark"> — </span>Infiltrative disorders such as sarcoidosis and Langerhans cell histiocytosis can cause deficiencies of anterior pituitary hormones and vasopressin. In a series of 12 patients with Langerhans cell histiocytosis, eight developed one or more anterior pituitary hormone deficiencies at a median of 4.5 years after their initial diagnosis of AVP-D [<a href="#rid12">12</a>]. Magnetic resonance imaging (MRI) of the sella region in patients who have hypopituitarism due to these infiltrative diseases often shows marked thickening of the infundibulum [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H523299318"><span class="h2">Infections</span><span class="headingEndMark"> — </span>Hypopituitarism can follow meningitis, which can be caused by many different kinds of infectious agents, including tuberculosis [<a href="#rid14">14</a>], candida [<a href="#rid15">15</a>], and hantavirus [<a href="#rid16">16</a>]. It is more likely in immunocompromised patients, such as by human immunodeficiency virus (HIV) [<a href="#rid17">17</a>] and high-dose glucocorticoids [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H1162920"><span class="h2">Traumatic brain injury</span><span class="headingEndMark"> — </span>Head trauma of sufficient severity to fracture the skull base can cause hypothalamic hormone deficiencies, resulting in deficient secretion of anterior pituitary hormones and vasopressin [<a href="#rid18">18</a>]. A number of studies also report hormonal deficiencies associated with trauma that does not fracture the skull base, but the frequency of such deficiencies is difficult to determine because some of the criteria for diagnosis of decreased secretion are less stringent than generally used to diagnose hypopituitarism [<a href="#rid19">19-24</a>]. Nonetheless, some generalizations can be made about hormonal abnormalities following traumatic brain injury [<a href="#rid25">25-27</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Anterior pituitary deficiencies are common acutely but much less common 3 and 12 months afterwards. In a study of 46 consecutive patients with traumatic brain injury, 35 patients (76 percent) had deficiencies in the acute phase, but only six (13 percent) and five (11 percent) had deficiencies 3 and 12 months afterwards [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The likelihood of hormonal deficiency is directly related to the severity of the injury. In the same study noted above, deficiencies 12 months after injury were found in 4 of 15 (27 percent) who had severe trauma and only 1 of 35 (3 percent) who had mild or moderate trauma [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypoadrenalism, hypothyroidism, and hypogonadism are less common than decreased GH response to an arginine-gonadotropin-releasing hormone (GHRH) stimulus. In the study cited above, 12 months after the trauma, three had hypoadrenalism, one hypothyroidism, one hypogonadism, and all five a subnormal GH response to stimulation [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities of vasopressin secretion are also common in the acute phase of the illness and less common later. In a study of 122 consecutive patients who experienced moderate to severe traumatic brain injury [<a href="#rid23">23</a>], 22 (18 percent) had AVP-D acutely, but persistent AVP-D was only seen in seven patients (6 percent) 6 to 36 months later. Thirteen patients (10.6 percent) had the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in the acute period, but only one did later.</p><p></p><p class="headingAnchor" id="H1163205"><span class="h2">Stroke</span><span class="headingEndMark"> — </span>Both ischemic stroke [<a href="#rid29">29,30</a>] and subarachnoid hemorrhage [<a href="#rid19">19</a>] may be associated with pituitary dysfunction, although not commonly.</p><p class="headingAnchor" id="H1163280"><span class="h3">Ischemic stroke</span><span class="headingEndMark"> — </span>In one report of 48 patients who underwent endocrine evaluation 12 to 15 months after an ischemic stroke, none were hypothyroid, one was hypoadrenal, three were hypogonadal, and 15 had subnormal GH response to GHRH stimulation [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1163300"><span class="h3">Subarachnoid hemorrhage</span><span class="headingEndMark"> — </span>Patients with subarachnoid hemorrhage may also be at risk for developing hypopituitarism. The prevalence varies widely from study to study [<a href="#rid19">19,31-34</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PITUITARY DISORDERS</span><span class="headingEndMark"> — </span>Any disease that affects the pituitary gland can result in diminished secretion of one or more pituitary hormones. These diseases include mass lesions, surgery and radiation to treat mass lesions, and many other disorders.</p><p class="headingAnchor" id="H4"><span class="h2">Mass lesions</span><span class="headingEndMark"> — </span>Mass lesions that can cause hypopituitarism include pituitary adenomas, cysts, metastatic cancer, and other lesions. The early stage of lymphocytic hypophysitis is characterized by lymphocytic infiltration and enlargement of the pituitary.</p><p>A mass lesion in the sella can cause temporary or permanent damage by exerting pressure on pituitary cells. Conversely, reducing the size of the mass may relieve the pressure and restore pituitary function. (See  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses"</a>.)</p><p class="headingAnchor" id="H13251199"><span class="h3">Pituitary macroadenomas</span><span class="headingEndMark"> — </span>Among pituitary mass lesions, pituitary adenomas are most commonly associated with hypopituitarism, in particular, clinically nonfunctioning pituitary adenomas (see <a class="local">'Epidemiology'</a> above and  <a class="medical medical_review" href="/d/html/6627.html" rel="external">"Clinical manifestations and diagnosis of gonadotroph and other clinically nonfunctioning pituitary adenomas"</a>). In a retrospective study of 305 patients who were to have transsphenoidal surgery for a clinically nonfunctioning pituitary adenoma, 50 percent had hormonal deficits preoperatively; 26 percent were hypothyroid, 20 percent of males and 16 percent of females were hypogonadal, and 13 percent were hypoadrenal [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Pituitary surgery</span><span class="headingEndMark"> — </span>A surgeon who excises a pituitary adenoma attempts to preserve the adjacent nonadenomatous pituitary, but that goal may not be possible if the two cannot be distinguished visually. If sufficient normal tissue is inadvertently excised, hypopituitarism will occur. Consequently, pituitary function may be better or worse afterwards (see  <a class="medical medical_review" href="/d/html/86683.html" rel="external">"Transsphenoidal surgery for pituitary adenomas and other sellar masses", section on 'Hormonal deficiencies'</a>). In the same review above [<a href="#rid35">35</a>], pituitary function improved six weeks and six months after surgery in 26 and 36 percent of men who had been hypogonadal, 13 and 13 percent of women who had been hypogonadal, 30 and 49 percent of those who had been hypothyroid, and 3 and 3 percent of those who had been hypoadrenal.</p><p class="headingAnchor" id="H6"><span class="h2">Pituitary radiation</span><span class="headingEndMark"> — </span>Radiation of a pituitary adenoma, usually to prevent regrowth of residual tissue after surgery, exposes the nonadenomatous pituitary to the same radiation. In one report of 22 patients who received supervoltage radiation (46 Gy) of residual adenoma tissue after surgery, over 50 percent developed new corticotropin (ACTH), thyroid-stimulating hormone (TSH), or gonadotropin (luteinizing hormone [LH]/follicle-stimulating hormone [FSH]) deficiency during the subsequent four years [<a href="#rid36">36</a>]. The results of other studies were similar [<a href="#rid37">37,38</a>].</p><p>Because single high-dose radiation from a gamma or proton beam source or linear accelerator (stereotactic "radiosurgery") is usually administered to a smaller volume of tissue than fractionated radiation, the expectation was that the risk of hypopituitarism would be less. However, these forms of radiation also cause a similar, high rate of hypopituitarism in the subsequent decade [<a href="#rid39">39</a>]. In a report based upon a prospective database of patients who had gamma radiation for acromegaly or Cushing disease at least five years and a median of more than 13 years earlier, the actuarial rates of hypopituitarism at 3, 5, and 10 years were 10, 21.7, and 53.3 percent [<a href="#rid40">40</a>]. Because loss of any pituitary hormone can occur from a few months to at least 10 years after radiation, hormonal evaluation should be performed six months afterwards and then yearly. (See  <a class="medical medical_review" href="/d/html/86684.html" rel="external">"Radiation therapy of pituitary adenomas"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Hereditary hemochromatosis</span><span class="headingEndMark"> — </span>Hemochromatosis in the pituitary is characterized by iron deposition in pituitary cells. Gonadotropin deficiency is the most common endocrine abnormality; other pituitary hormone deficiencies may occur but are much less common [<a href="#rid41">41</a>]. Repeated phlebotomy to remove iron may reverse the gonadotropin deficiency [<a href="#rid42">42</a>]. (See  <a class="medical medical_review" href="/d/html/7167.html" rel="external">"Clinical manifestations and diagnosis of hereditary hemochromatosis"</a> and  <a class="medical medical_review" href="/d/html/7136.html" rel="external">"Management and prognosis of hereditary hemochromatosis"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Hypophysitis</span><span class="headingEndMark"> — </span>Several uncommon forms of hypophysitis (inflammation of the pituitary) are recognized histologically, including lymphocytic, granulomatous, plasmacytic, and xanthomatous [<a href="#rid43">43,44</a>]. The clinical and hormonal manifestations are similar for all of them and are described below.</p><p class="headingAnchor" id="H151810110"><span class="h3">Lymphocytic hypophysitis</span><span class="headingEndMark"> — </span>Lymphocytic hypophysitis is the most common form of hypophysitis; the cause is usually unknown. It is initially characterized by lymphocytic infiltration and enlargement of the pituitary; this stage is followed by destruction of the pituitary cells [<a href="#rid45">45-47</a>]. It often occurs in late pregnancy or the postpartum period. In a report of 16 patients, there were 14 females and 2 males; the clinical presentation was associated with pregnancy in 10 of the women. The frequent postpartum occurrence and the lymphocytic infiltration suggest that this disorder has an autoimmune etiology [<a href="#rid45">45</a>]. One report, however, showed a majority of patients whose diagnosis was independent of pregnancy [<a href="#rid48">48</a>].</p><p>Affected patients typically present with headaches of an intensity out of proportion to the size of the lesion and with hypopituitarism. Preferential hypofunction of ACTH- and TSH-secreting cells has been described in many papers, leading to adrenal insufficiency and hypothyroidism [<a href="#rid49">49</a>], but hypogonadism was most common in a more recent study [<a href="#rid48">48</a>]. Arginine vasopressin deficiency (AVP-D), hyperprolactinemia, growth hormone (GH) excess, and associated autoimmune thyroiditis can also occur [<a href="#rid11">11,45,50</a>].</p><p>Magnetic resonance imaging (MRI) typically reveal features of a pituitary mass, mimicking an adenoma [<a href="#rid11">11,45</a>]. MRI also shows diffuse and homogeneous contrast enhancement of the anterior pituitary [<a href="#rid49">49</a>], but enhancement may be delayed or even absent in the posterior pituitary area [<a href="#rid11">11</a>].</p><p>The natural history typically involves progressive pituitary atrophy with replacement of pituitary tissue by fibrosis [<a href="#rid46">46</a>]. However, at least partial spontaneous recovery of both anterior and posterior pituitary function can occur [<a href="#rid45">45,46</a>]. High-dose pulse glucocorticoid therapy has been reported to reduce the mass effect in a small number of patients [<a href="#rid51">51,52</a>].</p><p class="headingAnchor" id="H13251309"><span class="h4">Complication of immunotherapy</span><span class="headingEndMark"> — </span>Hypophysitis may also occur as a complication of anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) immunotherapy, mostly with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>. In a review of three studies of more than 100 patients each who were treated with ipilimumab, hypophysitis was diagnosed in 11 to 17 percent based on the combination of headache, pituitary enlargement (<a class="graphic graphic_diagnosticimage graphicRef96625" href="/d/graphic/96625.html" rel="external">image 1</a>), and hypopituitarism [<a href="#rid53">53</a>]. Most patients had all three conditions. The pituitary enlargement was not associated with visual impairment. The diagnosis was made a median of 8 to 10 weeks after beginning treatment. In most patients, the pituitary enlargement eventually resolved, but hypopituitarism was usually permanent. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors", section on 'Hypophysitis'</a>.)</p><p class="headingAnchor" id="H434976"><span class="h3">Granulomatous hypophysitis</span><span class="headingEndMark"> — </span>This condition is characterized histologically by infiltration by histiocytes and giant cells [<a href="#rid43">43,44</a>]. It sometimes accompanies a known systemic granulomatous condition, such as Wegener granulomatosis and tuberculosis, and has been reported following treatment of hepatitis C with interferon alfa and <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> [<a href="#rid54">54</a>], but the cause is often unknown. The clinical and hormonal manifestations are similar to those of lymphocytic hypophysitis, although one report described a greater percentage of chiasmal involvement with granulomatous hypophysitis [<a href="#rid48">48</a>].</p><p class="headingAnchor" id="H434983"><span class="h3">Plasmacytic (IgG4-associated) hypophysitis</span><span class="headingEndMark"> — </span>Histologically, this is characterized by infiltration by plasma cells, which produce immunoglobulin G4 (IgG4) [<a href="#rid43">43</a>]. Infiltration of the pituitary is often associated with infiltration of other organs, such as the pancreas. This disorder may be more common than previously thought. In a report of 170 patients with hypopituitarism, of whom 23 had hypophysitis, seven were diagnosed with IgG4-related hypophysitis, giving a prevalence of 30 and 4 percent of hypophysitis and all hypopituitarism cases, respectively [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H434990"><span class="h3">Xanthomatous hypophysitis</span><span class="headingEndMark"> — </span>This condition, the most rare form of hypophysitis, is characterized histologically by infiltration by foamy histiocytes [<a href="#rid43">43,44</a>].</p><p class="headingAnchor" id="H10"><span class="h2">Pituitary infarction (Sheehan syndrome)</span><span class="headingEndMark"> — </span>Infarction of the pituitary gland after postpartum hemorrhage has long been recognized as a cause of hypopituitarism and is called Sheehan syndrome [<a href="#rid56">56,57</a>]. In developed countries, postpartum hemorrhage now less often results in Sheehan syndrome than previously, largely due to improvements in obstetrical care [<a href="#rid58">58</a>], but it does still occur. However, in resource-limited countries, postpartum pituitary infarction remains a common cause of hypopituitarism [<a href="#rid59">59</a>]. Less commonly, infarction may occur immediately postpartum even in the absence of obvious hemorrhage. (See  <a class="medical medical_review" href="/d/html/6710.html" rel="external">"Overview of postpartum hemorrhage"</a>.)</p><p>In a report of 114 patients with Sheehan syndrome, 53, 31, and 10 percent of women had nonspecific symptoms, symptoms suggestive of adrenal insufficiency, or symptoms of hypogonadism, respectively [<a href="#rid60">60</a>]. The mean diagnostic delay was 19.7 years, possibly related to the high percentage of women with nonspecific symptoms. At the time of diagnosis, 55 percent had panhypopituitarism and 45 percent had partial hypopituitarism.</p><p>Clinical features of Sheehan syndrome include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A history of postpartum hemorrhage so severe as to cause hypotension and require transfusion of multiple units of blood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the hypopituitarism is severe, development of lethargy, anorexia, weight loss, and inability to lactate during the first days or weeks after delivery [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the hypopituitarism is less severe, failure of postpartum lactation and failure to resume menses in the weeks and months after delivery [<a href="#rid57">57,61,62</a>] and loss of sexual hair, as well as milder degrees of fatigue, anorexia, and weight loss.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the hypopituitarism is mild, possible delay in recognition for many years after the inciting event [<a href="#rid57">57,61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Loss of all anterior pituitary hormones. In two reports of a total of 48 women with Sheehan syndrome due to severe postpartum hemorrhage, all patients had GH, prolactin, and gonadotropin deficiency, and the majority had TSH and ACTH deficiency [<a href="#rid61">61,62</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rare development of overt arginine vasopressin deficiency (AVP-D), although subclinical vasopressin deficiency is common [<a href="#rid63">63-65</a>]. (See  <a class="medical medical_review" href="/d/html/2373.html" rel="external">"Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Eventual development of a small pituitary within a sella of normal size, sometimes read as an "empty sella" on MRI [<a href="#rid57">57,66</a>].</p><p></p><p>Evaluation of postpartum hypopituitarism should be performed whenever it is suspected after a delivery associated with unusually heavy blood loss. If the blood loss is severe and especially if it is associated with hypotension, the patient should be evaluated and treated for adrenal insufficiency immediately. Other hormonal deficiencies can be evaluated four to six weeks later. (See  <a class="medical medical_review" href="/d/html/6639.html" rel="external">"Diagnostic testing for hypopituitarism"</a>.)</p><p>Treatment is the same as for other causes of hypopituitarism (see  <a class="medical medical_review" href="/d/html/6640.html" rel="external">"Treatment of hypopituitarism"</a>). Prolactin deficiency results in inability to breastfeed, but no treatment is available. The value of measuring prolactin shortly after postpartum hemorrhage to predict the ability to breastfeed has not been studied.</p><p>Rare causes of pituitary infarction include:</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular insufficiency occurring during coronary artery bypass surgery in older patients [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Snake bites in Southeast Asia (Russell's viper bites) – 49 cases of acute and/or chronic hypopituitarism have been reported [<a href="#rid68">68</a>]. Autopsy studies of most patients have shown hemorrhagic necrosis of the pituitary. (See  <a class="medical medical_review" href="/d/html/6594.html" rel="external">"Snakebites worldwide: Clinical manifestations and diagnosis", section on 'Additional resources'</a> and  <a class="medical medical_review" href="/d/html/93182.html" rel="external">"Snakebites worldwide: Management", section on 'Additional resources'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Pituitary apoplexy</span><span class="headingEndMark"> — </span>Sudden hemorrhage into the pituitary gland is called pituitary apoplexy. Hemorrhage often occurs into a pituitary adenoma. In one report, the prevalence of pituitary apoplexy among patients with nonfunctioning pituitary macroadenomas was 8 percent [<a href="#rid69">69</a>]. In its most dramatic presentation, apoplexy causes the sudden onset of excruciating headache, diplopia due to pressure on the oculomotor nerves, and hypopituitarism. All pituitary hormonal deficiencies can occur, but the sudden onset of ACTH and therefore cortisol deficiency is the most serious because it can cause life-threatening hypotension.</p><p>The sudden enlargement of the pituitary mass, due to acute hemorrhage, results in a range of acute clinical findings (severe headache, visual loss, diplopia, hypopituitarism) [<a href="#rid70">70</a>]. The acute symptoms and imaging evidence of a pituitary mass confirms the diagnosis.</p><p>In a series of 35 patients with pituitary apoplexy seen at one center, 97 percent had headache, 71 percent had visual field impairment, and 66 percent had decreased visual acuity [<a href="#rid71">71</a>]. Only a minority had clinical manifestations of hormonal excess or deficiency, but there was biochemical evidence of gonadotropin deficiency in 79 percent, ACTH deficiency in 76 percent, and TSH deficiency in 50 percent. MRI revealed hemorrhage more often than did computed tomography (CT).</p><p>Surgical decompression of the pituitary is often performed in cases with severe or progressive impairment of vision or neurologic symptoms [<a href="#rid70">70</a>]. The hypopituitarism, like the diplopia, may improve after surgical decompression [<a href="#rid71">71,72</a>]. Both problems may also improve spontaneously, as blood is resorbed, over a course of weeks to months after the hemorrhage. Other treatments that can be used include high doses of corticosteroids and, for patients with a lactotroph adenoma, administration of a dopamine agonist to reduce adenoma size. (See  <a class="medical medical_review" href="/d/html/6630.html" rel="external">"Management of hyperprolactinemia"</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Pituitary infection/abscess</span><span class="headingEndMark"> — </span>Infections in the pituitary are rare and can be due to a variety of organisms, as infections in the hypothalamus (see <a class="local">'Infections'</a> above). Some infections result in an abscess of the pituitary [<a href="#rid73">73</a>]. These present with headaches, and MRI shows a mass of &gt;1 cm in diameter. Most patients have panhypopituitarism, and several have AVP-D. In a few cases, culture of the pus aspirated at transsphenoidal surgery identifies the apparent infectious agent.</p><p class="headingAnchor" id="H13"><span class="h2">Genetic diseases</span><span class="headingEndMark"> — </span>For many years, congenital deficiencies of one or more pituitary hormones have been recognized. The genetic defects responsible for some of the congenital deficiencies been identified [<a href="#rid74">74</a>]. These defects are in the genes that encode the transcription factors whose expression is necessary, in cascade, for the differentiation of anterior pituitary cells (<a class="graphic graphic_table graphicRef80512" href="/d/graphic/80512.html" rel="external">table 2</a>).</p><p>Mutations have so far been detected in the genes encoding many of these transcription factors, including:</p><p class="bulletIndent1"><span class="glyph">●</span>ROBOS guidance receptors (ROBOS) determine axonal guidance in the central nervous system [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BMP4 induces Rathke's pouch formation, which is necessary for anterior pituitary development [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>HESX1 </em>[<a href="#rid77">77,78</a>], <em>LHX3 </em>[<a href="#rid79">79</a>], and <em>LHX4</em> [<a href="#rid80">80</a>], transcription factors that are important for pituitary organogenesis and early differentiation of pituicytes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PROP-1, which is necessary for the differentiation of a cell type that is a precursor to somatotroph, lactotroph, thyrotroph, and gonadotroph cells.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PIT-1 (called <em>POU1F1</em> in the human), which acts temporally just after PROP-1 and is necessary for the differentiation of a cell type that is a precursor of somatotroph, lactotroph, and, to a lesser degree, thyrotroph cells [<a href="#rid81">81-84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>TPIT</em>, which is required for specific differentiation of the corticotroph cells. (See  <a class="medical medical_review" href="/d/html/2900.html" rel="external">"Basic genetics concepts: DNA regulation and gene expression"</a>.)</p><p></p><p class="headingAnchor" id="H343364653"><span class="h3">ROBO1</span><span class="headingEndMark"> — </span>A <em>ROBO1</em> mutation has been reported to cause combined anterior hormone deficiencies and severe central nervous system abnormalities [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H2232653467"><span class="h3">BMP4</span><span class="headingEndMark"> — </span>Mutation in <em>BMP4</em> has been reported to result in combined anterior pituitary hormone deficiencies and central nervous system abnormalities [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H338524611"><span class="h3">HEXS1, LHX3, LHX4</span><span class="headingEndMark"> — </span>Mutations in <em>HEXS1</em>, <em>LHX3</em>, and <em>LHX4</em>, because they act early in pituicyte differentiation, cause combined pituitary hormone deficiency, which refers to deficiencies of GH, prolactin, TSH, LH, and FSH [<a href="#rid77">77,79,80</a>]. Mutations in <em>LHX3</em> also lead to neurologic abnormalities due to expression in the central nervous system (CNS) [<a href="#rid86">86</a>].</p><p class="headingAnchor" id="H338524618"><span class="h3">PROP-1</span><span class="headingEndMark"> — </span>Mutations in PROP-1 appear to be the most common cause of both familial and sporadic congenital combined pituitary hormone deficiency [<a href="#rid81">81,87-89</a>]. This was illustrated in a study of 195 patients with sporadic or familial combined pituitary hormone deficiency [<a href="#rid82">82</a>], in whom <em>PROP1</em> mutations were identified in 20 of 109 patients without extrapituitary abnormalities, <em>POU1F1</em> and <em>LHX4</em> mutations in one patient each, and no mutations in <em>LHX3</em> or <em>HESX1</em>. ACTH deficiency has been described in several older patients with PROP-1<em> </em>mutations [<a href="#rid90">90</a>], but it is not known whether ACTH deficiency in these patients is a result of corticotroph attrition or pituitary hypertrophy followed by pituitary degeneration, which has been described in some patients with these mutations.</p><p>Several different mutations have been detected, and the phenotypic results are variable, even in patients who have the same mutation. The age of onset of the first hormonal deficiency, the order of the onset of the various pituitary hormone deficiencies, and the severity of the deficiencies all vary. Almost invariably, however, GH deficiency begins sometime in infancy or childhood and results in short stature. Most patients receive GH therapy during childhood. However, in a family of three individuals with <em>PROP-1</em> mutations who did not receive GH therapy until adulthood, significant linear growth occurred in spite of their fairly advanced bone age [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H338524625"><span class="h3">PIT-1</span><span class="headingEndMark"> — </span>Both dominant and recessive mutations of the gene that encodes PIT-1 (<em>POU1F1</em>) lead to congenital deficiencies of GH, prolactin, and sometimes TSH [<a href="#rid82">82,83</a>]. The secretion of ACTH, FSH, and LH is preserved. A study of four affected siblings found that all had complete deficiency of GH diagnosed in early childhood, while central hypothyroidism and hypoprolactinemia developed later [<a href="#rid82">82</a>].</p><p>Circulating anti-PIT-1 antibodies may also result in hypopituitarism. This was illustrated in a report of three patients with adult onset GH, prolactin, and TSH deficiency and antibodies against the PIT-1 gene [<a href="#rid92">92</a>]. None had evidence of the autoantibodies described with autoimmune polyglandular syndrome-associated hypophysitis (anti-GH, anti-alpha-enolase, anti-TDRD6), suggesting that these are different autoimmune disorders.</p><p class="headingAnchor" id="H338524632"><span class="h3">TPIT</span><span class="headingEndMark"> — </span>Because the <em>TPIT </em>gene is necessary for differentiation of the corticotroph cell, mutations of the gene are one cause of isolated ACTH deficiency, which results in neonatal death if not detected early [<a href="#rid93">93</a>]. Other genetic causes of isolated ACTH deficiency are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/173.html" rel="external">"Causes of secondary and tertiary adrenal insufficiency in adults", section on 'Isolated ACTH deficiency'</a>.)</p><p class="headingAnchor" id="H1071912"><span class="h2">Pituitary stalk interruption syndrome</span><span class="headingEndMark"> — </span>Congenital hypopituitarism is often associated with the imaging abnormalities of a small pituitary, thinned or interrupted stalk, and ectopic neurohypophysis, together called the pituitary stalk interruption syndrome (PSIS) [<a href="#rid94">94,95</a>], although it is a radiologic constellation and not clinical syndrome. This constellation may also be associated with one of the mutations above [<a href="#rid94">94</a>]; there is also some evidence for a polygenic cause of PSIS [<a href="#rid96">96</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Empty sella</span><span class="headingEndMark"> — </span>An empty sella refers to an enlarged sella turcica that is not entirely filled with pituitary tissue. It is a radiologic description and not a clinical condition. There are two types:</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary empty sella is characterized by association of the empty sella with an identifiable disease of the pituitary gland. One example of an identifiable disease is a mass, such as a pituitary adenoma, that enlarges the sella but then is removed by surgery, radiation, or infarction. In this type of empty sella, hypopituitarism can result from the adenoma itself, its treatment, or infarction. A remnant of a partially removed pituitary adenoma could have residual function. Another example is a congenital abnormality of a transcription factor necessary for pituitary differentiation, where the sella turcica is normal but the pituitary gland is small [<a href="#rid97">97</a>]. (See <a class="local">'PROP-1'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary empty sella is characterized by a defect in the diaphragm sella that is thought to allow cerebrospinal fluid (CSF) pressure to enlarge the sella [<a href="#rid98">98</a>]. Although some papers claim deficiencies of one or more pituitary hormones [<a href="#rid99">99</a>], the evidence for such deficiencies is not convincing, ie, there is no consistent evidence of the existence of an "empty sella syndrome."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of a patient whose MRI shows an empty or partially empty sella, therefore, depends on what else is seen in the sella and the clinical situation. The presence of a sellar mass, especially a lesion more than 1 cm in size, requires evaluation for hormonal hypersecretion and hyposecretion, as does any other sellar mass. Clinical evidence of hormonal excess or deficiencies requires biochemical evaluation of all pituitary hormones. In the absence of a sellar mass and clinical evidence of hormonal excess or deficiency, measurement of thyroxine (T4) and early morning cortisol could be performed, but the likelihood is that they will be normal. (See  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses"</a>.)</p><p></p><p class="headingAnchor" id="H3931603909"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116762.html" rel="external">"Society guideline links: Pituitary tumors and hypopituitarism"</a>.)</p><p class="headingAnchor" id="H28694411"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/83818.html" rel="external">"Patient education: Panhypopituitarism (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H173302317"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition </strong>– Hypopituitarism refers to decreased secretion of pituitary hormones, which can result from diseases of the hypothalamus or pituitary gland (<a class="graphic graphic_table graphicRef55951" href="/d/graphic/55951.html" rel="external">table 1</a>). The majority of cases are due to a pituitary adenoma or treatment of the adenoma or, less commonly, an extrapituitary tumor (eg, craniopharyngioma).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypothalamic disorders </strong>–<strong> </strong>Any disease involving the hypothalamus can affect secretion of one or more of the hypothalamic hormones that influence secretion of corresponding pituitary hormones (<a class="graphic graphic_table graphicRef55951" href="/d/graphic/55951.html" rel="external">table 1</a>). (See <a class="local">'Hypothalamic disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Benign tumors such as craniopharyngiomas. (See <a class="local">'Tumors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Malignant tumors that metastasize to the hypothalamic area, such as lung and breast carcinomas. (See  <a class="medical medical_review" href="/d/html/6632.html" rel="external">"Causes, presentation, and evaluation of sellar masses"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cranial radiation for brain tumors, which can result in hypothalamic hormone and, therefore, pituitary hormone deficiency. (See <a class="local">'Radiation therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infiltrative diseases such as sarcoidosis and Langerhans cell histiocytosis. (See <a class="local">'Infiltrative lesions'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other causes of hypopituitarism include traumatic brain injury and stroke (ischemic and subarachnoid hemorrhage). (See <a class="local">'Traumatic brain injury'</a> above and <a class="local">'Stroke'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pituitary disorders </strong>–<strong> </strong>In addition to pituitary adenomas and their treatment (surgery or radiation therapy), a number of other pituitary disorders can cause hypopituitarism (<a class="graphic graphic_table graphicRef55951" href="/d/graphic/55951.html" rel="external">table 1</a>). (See <a class="local">'Pituitary disorders'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other types of pituitary masses, including metastatic disease.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Infiltrative lesions (hemochromatosis, lymphocytic hypophysitis). (See <a class="local">'Hereditary hemochromatosis'</a> above and <a class="local">'Hypophysitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pituitary infarction (Sheehan syndrome) or hemorrhage. (See <a class="local">'Pituitary infarction (Sheehan syndrome)'</a> above and <a class="local">'Pituitary apoplexy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Mutations in genes that encode transcription factors, such as PROP-1, <em>POU1F1</em>, <em>TPIT</em>, <em>HESX1</em>, <em>LHX3</em>, and <em>LHX4</em>, that are important for differentiation of different pituitary cell types and/or pituitary organogenesis (<a class="graphic graphic_table graphicRef80512" href="/d/graphic/80512.html" rel="external">table 2</a>). (See <a class="local">'Genetic diseases'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Regal M, Páramo C, Sierra SM, Garcia-Mayor RV. Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. Clin Endocrinol (Oxf) 2001; 55:735.</a></li><li><a class="nounderline abstract_t">Tanriverdi F, Dokmetas HS, Kebapcı N, et al. Etiology of hypopituitarism in tertiary care institutions in Turkish population: analysis of 773 patients from Pituitary Study Group database. Endocrine 2014; 47:198.</a></li><li><a class="nounderline abstract_t">Constine LS, Woolf PD, Cann D, et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328:87.</a></li><li><a class="nounderline abstract_t">Samaan NA, Bakdash MM, Caderao JB, et al. Hypopituitarism after external irradiation. Evidence for both hypothalamic and pituitary origin. Ann Intern Med 1975; 83:771.</a></li><li><a class="nounderline abstract_t">Lam KS, Wang C, Yeung RT, et al. Hypothalamic hypopituitarism following cranial irradiation for nasopharyngeal carcinoma. Clin Endocrinol (Oxf) 1986; 24:643.</a></li><li><a class="nounderline abstract_t">Achermann JC, Hindmarsh PC, Brook CG. The relationship between the growth hormone and insulin-like growth factor axis in long-term survivors of childhood brain tumours. Clin Endocrinol (Oxf) 1998; 49:639.</a></li><li><a class="nounderline abstract_t">Agha A, Sherlock M, Brennan S, et al. Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults. J Clin Endocrinol Metab 2005; 90:6355.</a></li><li><a class="nounderline abstract_t">Appelman-Dijkstra NM, Kokshoorn NE, Dekkers OM, et al. Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96:2330.</a></li><li><a class="nounderline abstract_t">Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA 2013; 309:2371.</a></li><li><a class="nounderline abstract_t">Chemaitilly W, Li Z, Huang S, et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol 2015; 33:492.</a></li><li><a class="nounderline abstract_t">Sato N, Sze G, Endo K. Hypophysitis: endocrinologic and dynamic MR findings. AJNR Am J Neuroradiol 1998; 19:439.</a></li><li><a class="nounderline abstract_t">Kaltsas GA, Powles TB, Evanson J, et al. Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab 2000; 85:1370.</a></li><li><a class="nounderline abstract_t">Imashuku S, Kudo N, Kaneda S, et al. Treatment of patients with hypothalamic-pituitary lesions as adult-onset Langerhans cell histiocytosis. Int J Hematol 2011; 94:556.</a></li><li><a class="nounderline abstract_t">Lam KS, Sham MM, Tam SC, et al. Hypopituitarism after tuberculous meningitis in childhood. Ann Intern Med 1993; 118:701.</a></li><li><a class="nounderline abstract_t">Morichika D, Sato-Hisamoto A, Hotta K, et al. Fatal Candida septic shock during systemic chemotherapy in lung cancer patient receiving corticosteroid replacement therapy for hypopituitarism: a case report. Jpn J Clin Oncol 2014; 44:501.</a></li><li><a class="nounderline abstract_t">Bhoelan S, Langerak T, Noack D, et al. Hypopituitarism after Orthohantavirus Infection: What is Currently Known? Viruses 2019; 11.</a></li><li><a class="nounderline abstract_t">Harbeck B, Klose S, Buchfelder M, et al. Hypopituitarism in a HIV affected patient. Exp Clin Endocrinol Diabetes 2011; 119:633.</a></li><li><a class="nounderline abstract_t">Edwards OM, Clark JD. Post-traumatic hypopituitarism. Six cases and a review of the literature. Medicine (Baltimore) 1986; 65:281.</a></li><li><a class="nounderline abstract_t">Schneider HJ, Aimaretti G, Kreitschmann-Andermahr I, et al. Hypopituitarism. Lancet 2007; 369:1461.</a></li><li><a class="nounderline abstract_t">Benvenga S, Campenní A, Ruggeri RM, Trimarchi F. Clinical review 113: Hypopituitarism secondary to head trauma. J Clin Endocrinol Metab 2000; 85:1353.</a></li><li><a class="nounderline abstract_t">Lieberman SA, Oberoi AL, Gilkison CR, et al. Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. J Clin Endocrinol Metab 2001; 86:2752.</a></li><li><a class="nounderline abstract_t">Benvenga S, Vigo T, Ruggeri RM, et al. Severe head trauma in patients with unexplained central hypothyroidism. Am J Med 2004; 116:767.</a></li><li><a class="nounderline abstract_t">Agha A, Thornton E, O'Kelly P, et al. Posterior pituitary dysfunction after traumatic brain injury. J Clin Endocrinol Metab 2004; 89:5987.</a></li><li><a class="nounderline abstract_t">Aimaretti G, Ambrosio MR, Di Somma C, et al. Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab 2005; 90:6085.</a></li><li><a class="nounderline abstract_t">Cuesta M, Hannon MJ, Crowley RK, et al. Symptoms of gonadal dysfunction are more predictive of hypopituitarism than nonspecific symptoms in screening for pituitary dysfunction following moderate or severe traumatic brain injury. Clin Endocrinol (Oxf) 2016; 84:92.</a></li><li><a class="nounderline abstract_t">Tritos NA, Yuen KC, Kelly DF, AACE Neuroendocrine and Pituitary Scientific Committee. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: A NEUROENDOCRINE APPROACH TO PATIENTS WITH TRAUMATIC BRAIN INJURY. Endocr Pract 2015; 21:823.</a></li><li><a class="nounderline abstract_t">Tanriverdi F, Schneider HJ, Aimaretti G, et al. Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach. Endocr Rev 2015; 36:305.</a></li><li><a class="nounderline abstract_t">Klose M, Juul A, Struck J, et al. Acute and long-term pituitary insufficiency in traumatic brain injury: a prospective single-centre study. Clin Endocrinol (Oxf) 2007; 67:598.</a></li><li><a class="nounderline abstract_t">Bondanelli M, Ambrosio MR, Carli A, et al. Predictors of pituitary dysfunction in patients surviving ischemic stroke. J Clin Endocrinol Metab 2010; 95:4660.</a></li><li><a class="nounderline abstract_t">Bondanelli M, Ambrosio MR, Onofri A, et al. Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome. J Clin Endocrinol Metab 2006; 91:3928.</a></li><li><a class="nounderline abstract_t">Klose M, Brennum J, Poulsgaard L, et al. Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage. Clin Endocrinol (Oxf) 2010; 73:95.</a></li><li><a class="nounderline abstract_t">Schneider HJ, Kreitschmann-Andermahr I, Ghigo E, et al. Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA 2007; 298:1429.</a></li><li><a class="nounderline abstract_t">Hannon MJ, Behan LA, O'Brien MM, et al. Chronic hypopituitarism is uncommon in survivors of aneurysmal subarachnoid haemorrhage. Clin Endocrinol (Oxf) 2015; 82:115.</a></li><li><a class="nounderline abstract_t">Kronvall E, Valdemarsson S, Säveland H, Nilsson OG. High prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a long-term prospective study using dynamic endocrine testing. World Neurosurg 2015; 83:574.</a></li><li><a class="nounderline abstract_t">Jahangiri A, Wagner JR, Han SW, et al. Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis. J Neurosurg 2016; 124:589.</a></li><li><a class="nounderline abstract_t">Snyder PJ, Fowble BF, Schatz NJ, et al. Hypopituitarism following radiation therapy of pituitary adenomas. Am J Med 1986; 81:457.</a></li><li><a class="nounderline abstract_t">Littley MD, Shalet SM, Beardwell CG, et al. Hypopituitarism following external radiotherapy for pituitary tumours in adults. Q J Med 1989; 70:145.</a></li><li><a class="nounderline abstract_t">Eastman RC, Gorden P, Roth J. Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab 1979; 48:931.</a></li><li><a class="nounderline abstract_t">Sheehan JP, Niranjan A, Sheehan JM, et al. Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 2005; 102:678.</a></li><li><a class="nounderline abstract_t">Cohen-Inbar O, Ramesh A, Xu Z, et al. Gamma knife radiosurgery in patients with persistent acromegaly or Cushing's disease: long-term risk of hypopituitarism. Clin Endocrinol (Oxf) 2016; 84:524.</a></li><li><a class="nounderline abstract_t">Charbonnel B, Chupin M, Le Grand A, Guillon J. Pituitary function in idiopathic haemochromatosis: hormonal study in 36 male patients. Acta Endocrinol (Copenh) 1981; 98:178.</a></li><li><a class="nounderline abstract_t">Kelly TM, Edwards CQ, Meikle AW, Kushner JP. Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 1984; 101:629.</a></li><li><a class="nounderline abstract_t">Leporati P, Landek-Salgado MA, Lupi I, et al. IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab 2011; 96:1971.</a></li><li><a class="nounderline abstract_t">Cheung CC, Ezzat S, Smyth HS, Asa SL. The spectrum and significance of primary hypophysitis. J Clin Endocrinol Metab 2001; 86:1048.</a></li><li><a class="nounderline abstract_t">Thodou E, Asa SL, Kontogeorgos G, et al. Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings. J Clin Endocrinol Metab 1995; 80:2302.</a></li><li><a class="nounderline abstract_t">Cosman F, Post KD, Holub DA, Wardlaw SL. Lymphocytic hypophysitis. Report of 3 new cases and review of the literature. Medicine (Baltimore) 1989; 68:240.</a></li><li><a class="nounderline abstract_t">Lupi I, Manetti L, Raffaelli V, et al. Diagnosis and treatment of autoimmune hypophysitis: a short review. J Endocrinol Invest 2011; 34:e245.</a></li><li><a class="nounderline abstract_t">Honegger J, Schlaffer S, Menzel C, et al. Diagnosis of Primary Hypophysitis in Germany. J Clin Endocrinol Metab 2015; 100:3841.</a></li><li><a class="nounderline abstract_t">Powrie JK, Powell M, Ayers AB, et al. Lymphocytic adenohypophysitis: magnetic resonance imaging features of two new cases and a review of the literature. Clin Endocrinol (Oxf) 1995; 42:315.</a></li><li><a class="nounderline abstract_t">Imura H, Nakao K, Shimatsu A, et al. Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus. N Engl J Med 1993; 329:683.</a></li><li><a class="nounderline abstract_t">Kristof RA, Van Roost D, Klingmüller D, et al. Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy? J Neurol Neurosurg Psychiatry 1999; 67:398.</a></li><li><a class="nounderline abstract_t">Chico A, Puig-Domingo M, Martul P, et al. Reversible endocrine dysfunction and pituitary stalk enlargement. J Endocrinol Invest 1998; 21:122.</a></li><li><a class="nounderline abstract_t">Faje A. Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 2016; 19:82.</a></li><li><a class="nounderline abstract_t">Tebben PJ, Atkinson JL, Scheithauer BW, Erickson D. Granulomatous adenohypophysitis after interferon and ribavirin therapy. Endocr Pract 2007; 13:169.</a></li><li><a class="nounderline abstract_t">Bando H, Iguchi G, Fukuoka H, et al. The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature. Eur J Endocrinol 2014; 170:161.</a></li><li><a class="nounderline abstract_t">Barkan AL. Pituitary atrophy in patients with Sheehan's syndrome. Am J Med Sci 1989; 298:38.</a></li><li><a class="nounderline abstract_t">Keleştimur F. Sheehan's syndrome. Pituitary 2003; 6:181.</a></li><li><a class="nounderline abstract_t">Feinberg EC, Molitch ME, Endres LK, Peaceman AM. The incidence of Sheehan's syndrome after obstetric hemorrhage. Fertil Steril 2005; 84:975.</a></li><li><a class="nounderline abstract_t">Zargar AH, Singh B, Laway BA, et al. Epidemiologic aspects of postpartum pituitary hypofunction (Sheehan's syndrome). Fertil Steril 2005; 84:523.</a></li><li><a class="nounderline abstract_t">Diri H, Tanriverdi F, Karaca Z, et al. Extensive investigation of 114 patients with Sheehan's syndrome: a continuing disorder. Eur J Endocrinol 2014; 171:311.</a></li><li><a class="nounderline abstract_t">Dökmetaş HS, Kilicli F, Korkmaz S, Yonem O. Characteristic features of 20 patients with Sheehan's syndrome. Gynecol Endocrinol 2006; 22:279.</a></li><li><a class="nounderline abstract_t">Sert M, Tetiker T, Kirim S, Kocak M. Clinical report of 28 patients with Sheehan's syndrome. Endocr J 2003; 50:297.</a></li><li><a class="nounderline abstract_t">Atmaca H, Tanriverdi F, Gokce C, et al. Posterior pituitary function in Sheehan's syndrome. Eur J Endocrinol 2007; 156:563.</a></li><li><a class="nounderline abstract_t">Bakiri F, Benmiloud M, Vallotton MB. Arginine-vasopressin in postpartum panhypopituitarism: urinary excretion and kidney response to osmolar load. J Clin Endocrinol Metab 1984; 58:511.</a></li><li><a class="nounderline abstract_t">Jialal I, Desai RK, Rajput MC. An assessment of posterior pituitary function in patients with Sheehan's syndrome. Clin Endocrinol (Oxf) 1987; 27:91.</a></li><li><a class="nounderline abstract_t">Bakiri F, Bendib SE, Maoui R, et al. The sella turcica in Sheehan's syndrome: computerized tomographic study in 54 patients. J Endocrinol Invest 1991; 14:193.</a></li><li><a class="nounderline abstract_t">Davies JS, Scanlon MF. Hypopituitarism after coronary artery bypass grafting. BMJ 1998; 316:682.</a></li><li><a class="nounderline abstract_t">Antonypillai CN, Wass JA, Warrell DA, Rajaratnam HN. Hypopituitarism following envenoming by Russell's vipers (Daboia siamensis and D. russelii) resembling Sheehan's syndrome: first case report from Sri Lanka, a review of the literature and recommendations for endocrine management. QJM 2011; 104:97.</a></li><li><a class="nounderline abstract_t">Vargas G, Gonzalez B, Guinto G, et al. Pituitary apoplexy in nonfunctioning pituitary macroadenomas: a case-control study. Endocr Pract 2014; 20:1274.</a></li><li><a class="nounderline abstract_t">Capatina C, Inder W, Karavitaki N, Wass JA. Management of endocrine disease: pituitary tumour apoplexy. Eur J Endocrinol 2015; 172:R179.</a></li><li><a class="nounderline abstract_t">Randeva HS, Schoebel J, Byrne J, et al. Classical pituitary apoplexy: clinical features, management and outcome. Clin Endocrinol (Oxf) 1999; 51:181.</a></li><li><a class="nounderline abstract_t">Arafah BM, Harrington JF, Madhoun ZT, Selman WR. Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy. J Clin Endocrinol Metab 1990; 71:323.</a></li><li><a class="nounderline abstract_t">Dalan R, Leow MK. Pituitary abscess: our experience with a case and a review of the literature. Pituitary 2008; 11:299.</a></li><li><a class="nounderline abstract_t">Gregory LC, Dattani MT. The Molecular Basis of Congenital Hypopituitarism and Related Disorders. J Clin Endocrinol Metab 2020; 105.</a></li><li><a class="nounderline abstract_t">Dateki S, Watanabe S, Mishima H, et al. A homozygous splice site ROBO1 mutation in a patient with a novel syndrome with combined pituitary hormone deficiency. J Hum Genet 2019; 64:341.</a></li><li><a class="nounderline abstract_t">Davis SW, Camper SA. Noggin regulates Bmp4 activity during pituitary induction. Dev Biol 2007; 305:145.</a></li><li><a class="nounderline abstract_t">Carvalho LR, Woods KS, Mendonca BB, et al. A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction. J Clin Invest 2003; 112:1192.</a></li><li><a class="nounderline abstract_t">Sobrier ML, Maghnie M, Vié-Luton MP, et al. Novel HESX1 mutations associated with a life-threatening neonatal phenotype, pituitary aplasia, but normally located posterior pituitary and no optic nerve abnormalities. J Clin Endocrinol Metab 2006; 91:4528.</a></li><li><a class="nounderline abstract_t">Netchine I, Sobrier ML, Krude H, et al. Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency. Nat Genet 2000; 25:182.</a></li><li><a class="nounderline abstract_t">Machinis K, Pantel J, Netchine I, et al. Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4. Am J Hum Genet 2001; 69:961.</a></li><li><a class="nounderline abstract_t">Wu W, Cogan JD, Pfäffle RW, et al. Mutations in PROP1 cause familial combined pituitary hormone deficiency. Nat Genet 1998; 18:147.</a></li><li><a class="nounderline abstract_t">Pellegrini-Bouiller I, Bélicar P, Barlier A, et al. A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency. J Clin Endocrinol Metab 1996; 81:2790.</a></li><li><a class="nounderline abstract_t">Pfäffle RW, DiMattia GE, Parks JS, et al. Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia. Science 1992; 257:1118.</a></li><li><a class="nounderline abstract_t">Turton JP, Reynaud R, Mehta A, et al. Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency. J Clin Endocrinol Metab 2005; 90:4762.</a></li><li><a class="nounderline abstract_t">Rodríguez-Contreras FJ, Marbán-Calzón M, Vallespín E, et al. Loss of function BMP4 mutation supports the implication of the BMP/TGF-β pathway in the etiology of combined pituitary hormone deficiency. Am J Med Genet A 2019; 179:1591.</a></li><li><a class="nounderline abstract_t">Bhangoo AP, Hunter CS, Savage JJ, et al. Clinical case seminar: a novel LHX3 mutation presenting as combined pituitary hormonal deficiency. J Clin Endocrinol Metab 2006; 91:747.</a></li><li><a class="nounderline abstract_t">Cogan JD, Wu W, Phillips JA 3rd, et al. The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency. J Clin Endocrinol Metab 1998; 83:3346.</a></li><li><a class="nounderline abstract_t">Flück C, Deladoey J, Rutishauser K, et al. Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg--&gt;Cys at codon 120 (R120C). J Clin Endocrinol Metab 1998; 83:3727.</a></li><li><a class="nounderline abstract_t">Rosenbloom AL, Almonte AS, Brown MR, et al. Clinical and biochemical phenotype of familial anterior hypopituitarism from mutation of the PROP1 gene. J Clin Endocrinol Metab 1999; 84:50.</a></li><li><a class="nounderline abstract_t">Pernasetti F, Toledo SP, Vasilyev VV, et al. Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene. J Clin Endocrinol Metab 2000; 85:390.</a></li><li><a class="nounderline abstract_t">Lee JK, Zhu YS, Cordero JJ, et al. Long-term growth hormone therapy in adulthood results in significant linear growth in siblings with a PROP-1 gene mutation. J Clin Endocrinol Metab 2004; 89:4850.</a></li><li><a class="nounderline abstract_t">Yamamoto M, Iguchi G, Takeno R, et al. Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans. J Clin Invest 2011; 121:113.</a></li><li><a class="nounderline abstract_t">Vallette-Kasic S, Brue T, Pulichino AM, et al. Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations. J Clin Endocrinol Metab 2005; 90:1323.</a></li><li><a class="nounderline abstract_t">Yang Y, Guo QH, Wang BA, et al. Pituitary stalk interruption syndrome in 58 Chinese patients: clinical features and genetic analysis. Clin Endocrinol (Oxf) 2013; 79:86.</a></li><li><a class="nounderline abstract_t">Wang W, Wang S, Jiang Y, et al. Relationship between pituitary stalk (PS) visibility and the severity of hormone deficiencies: PS interruption syndrome revisited. Clin Endocrinol (Oxf) 2015; 83:369.</a></li><li><a class="nounderline abstract_t">Zwaveling-Soonawala N, Alders M, Jongejan A, et al. Clues for Polygenic Inheritance of Pituitary Stalk Interruption Syndrome From Exome Sequencing in 20 Patients. J Clin Endocrinol Metab 2018; 103:415.</a></li><li><a class="nounderline abstract_t">Mendonca BB, Osorio MG, Latronico AC, et al. Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene. J Clin Endocrinol Metab 1999; 84:942.</a></li><li><a class="nounderline abstract_t">Kaufman B. The "empty" sella turcica--a manifestation of the intrasellar subarachnoid space. Radiology 1968; 90:931.</a></li><li><a class="nounderline abstract_t">De Marinis L, Bonadonna S, Bianchi A, et al. Primary empty sella. J Clin Endocrinol Metab 2005; 90:5471.</a></li></ol></div><div id="topicVersionRevision">Topic 6636 Version 32.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11895214" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24366641" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Etiology of hypopituitarism in tertiary care institutions in Turkish population: analysis of 773 patients from Pituitary Study Group database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8416438" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Hypothalamic-pituitary dysfunction after radiation for brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/812402" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypopituitarism after external irradiation. Evidence for both hypothalamic and pituitary origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3098456" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hypothalamic hypopituitarism following cranial irradiation for nasopharyngeal carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10197080" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The relationship between the growth hormone and insulin-like growth factor axis in long-term survivors of childhood brain tumours.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16144946" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Hypothalamic-pituitary dysfunction after irradiation of nonpituitary brain tumors in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21613351" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Pituitary dysfunction in adult patients after cranial radiotherapy: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23757085" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical ascertainment of health outcomes among adults treated for childhood cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25559807" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9541295" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Hypophysitis: endocrinologic and dynamic MR findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770168" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22015494" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of patients with hypothalamic-pituitary lesions as adult-onset Langerhans cell histiocytosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8460856" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hypopituitarism after tuberculous meningitis in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24646812" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Fatal Candida septic shock during systemic chemotherapy in lung cancer patient receiving corticosteroid replacement therapy for hypopituitarism: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30974852" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Hypopituitarism after Orthohantavirus Infection: What is Currently Known?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21922454" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Hypopituitarism in a HIV affected patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3018425" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Post-traumatic hypopituitarism. Six cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17467517" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Hypopituitarism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10770165" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Clinical review 113: Hypopituitarism secondary to head trauma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11397882" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15144914" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Severe head trauma in patients with unexplained central hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15579748" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Posterior pituitary dysfunction after traumatic brain injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16144947" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26252757" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Symptoms of gonadal dysfunction are more predictive of hypopituitarism than nonspecific symptoms in screening for pituitary dysfunction following moderate or severe traumatic brain injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26172127" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: A NEUROENDOCRINE APPROACH TO PATIENTS WITH TRAUMATIC BRAIN INJURY.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25950715" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Pituitary dysfunction after traumatic brain injury: a clinical and pathophysiological approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17880406" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acute and long-term pituitary insufficiency in traumatic brain injury: a prospective single-centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20660027" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Predictors of pituitary dysfunction in patients surviving ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16882751" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Predictive value of circulating insulin-like growth factor I levels in ischemic stroke outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20105184" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Hypopituitarism is uncommon after aneurysmal subarachnoid haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17895459" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24965315" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Chronic hypopituitarism is uncommon in survivors of aneurysmal subarachnoid haemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25514615" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : High prevalence of pituitary dysfunction after aneurysmal subarachnoid hemorrhage: a long-term prospective study using dynamic endocrine testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26252454" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Improved versus worsened endocrine function after transsphenoidal surgery for nonfunctional pituitary adenomas: rate, time course, and radiological analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3092668" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Hypopituitarism following radiation therapy of pituitary adenomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2594955" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Hypopituitarism following external radiotherapy for pituitary tumours in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/447799" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Conventional supervoltage irradiation is an effective treatment for acromegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871511" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26341248" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Gamma knife radiosurgery in patients with persistent acromegaly or Cushing's disease: long-term risk of hypopituitarism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6794282" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pituitary function in idiopathic haemochromatosis: hormonal study in 36 male patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6435491" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Hypogonadism in hemochromatosis: reversal with iron depletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21593109" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : IgG4-related hypophysitis: a new addition to the hypophysitis spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11238484" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : The spectrum and significance of primary hypophysitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629223" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Clinical case seminar: lymphocytic hypophysitis: clinicopathological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2661963" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Lymphocytic hypophysitis. Report of 3 new cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21750396" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Diagnosis and treatment of autoimmune hypophysitis: a short review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26262437" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Diagnosis of Primary Hypophysitis in Germany.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7758238" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lymphocytic adenohypophysitis: magnetic resonance imaging features of two new cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8345854" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10449568" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Lymphocytic hypophysitis: non-invasive diagnosis and treatment by high dose methylprednisolone pulse therapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9585387" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Reversible endocrine dysfunction and pituitary stalk enlargement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26186958" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17490932" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Granulomatous adenohypophysitis after interferon and ribavirin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24165017" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The prevalence of IgG4-related hypophysitis in 170 consecutive patients with hypopituitarism and/or central diabetes insipidus and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2750772" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Pituitary atrophy in patients with Sheehan's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15237929" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Sheehan's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16213852" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The incidence of Sheehan's syndrome after obstetric hemorrhage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16084902" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Epidemiologic aspects of postpartum pituitary hypofunction (Sheehan's syndrome).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24917653" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Extensive investigation of 114 patients with Sheehan's syndrome: a continuing disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16785150" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Characteristic features of 20 patients with Sheehan's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940458" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Clinical report of 28 patients with Sheehan's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17468192" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Posterior pituitary function in Sheehan's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6693547" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Arginine-vasopressin in postpartum panhypopituitarism: urinary excretion and kidney response to osmolar load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3652485" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : An assessment of posterior pituitary function in patients with Sheehan's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1906495" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The sella turcica in Sheehan's syndrome: computerized tomographic study in 54 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9522796" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Hypopituitarism after coronary artery bypass grafting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21115460" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hypopituitarism following envenoming by Russell's vipers (Daboia siamensis and D. russelii) resembling Sheehan's syndrome: first case report from Sri Lanka, a review of the literature and recommendations for endocrine management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25100377" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pituitary apoplexy in nonfunctioning pituitary macroadenomas: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25452466" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Management of endocrine disease: pituitary tumour apoplexy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10468988" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Classical pituitary apoplexy: clinical features, management and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2166068" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Improvement of pituitary function after surgical decompression for pituitary tumor apoplexy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17594523" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Pituitary abscess: our experience with a case and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31702014" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The Molecular Basis of Congenital Hypopituitarism and Related Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30692597" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A homozygous splice site ROBO1 mutation in a patient with a novel syndrome with combined pituitary hormone deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17359964" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Noggin regulates Bmp4 activity during pituitary induction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14561704" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A homozygous mutation in HESX1 is associated with evolving hypopituitarism due to impaired repressor-corepressor interaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16940453" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Novel HESX1 mutations associated with a life-threatening neonatal phenotype, pituitary aplasia, but normally located posterior pituitary and no optic nerve abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10835633" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Mutations in LHX3 result in a new syndrome revealed by combined pituitary hormone deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11567216" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Syndromic short stature in patients with a germline mutation in the LIM homeobox LHX4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9462743" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Mutations in PROP1 cause familial combined pituitary hormone deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8768831" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A new mutation of the gene encoding the transcription factor Pit-1 is responsible for combined pituitary hormone deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1509263" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Mutation of the POU-specific domain of Pit-1 and hypopituitarism without pituitary hypoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15928241" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31120642" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Loss of function BMP4 mutation supports the implication of the BMP/TGF-βpathway in the etiology of combined pituitary hormone deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16394081" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinical case seminar: a novel LHX3 mutation presenting as combined pituitary hormonal deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9745452" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : The PROP1 2-base pair deletion is a common cause of combined pituitary hormone deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9768691" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Phenotypic variability in familial combined pituitary hormone deficiency caused by a PROP1 gene mutation resulting in the substitution of Arg--&gt;Cys at codon 120 (R120C).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9920061" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Clinical and biochemical phenotype of familial anterior hypopituitarism from mutation of the PROP1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10634415" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Impaired adrenocorticotropin-adrenal axis in combined pituitary hormone deficiency caused by a two-base pair deletion (301-302delAG) in the prophet of Pit-1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472175" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Long-term growth hormone therapy in adulthood results in significant linear growth in siblings with a PROP-1 gene mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21123951" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Adult combined GH, prolactin, and TSH deficiency associated with circulating PIT-1 antibody in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15613420" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23199197" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pituitary stalk interruption syndrome in 58 Chinese patients: clinical features and genetic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25845766" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Relationship between pituitary stalk (PS) visibility and the severity of hormone deficiencies: PS interruption syndrome revisited.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29165578" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Clues for Polygenic Inheritance of Pituitary Stalk Interruption Syndrome From Exome Sequencing in 20 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10084575" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Longitudinal hormonal and pituitary imaging changes in two females with combined pituitary hormone deficiency due to deletion of A301,G302 in the PROP1 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5300448" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : The "empty" sella turcica--a manifestation of the intrasellar subarachnoid space.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15972577" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Primary empty sella.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
